Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Daunorubicin Citrate

FDA-approved product (injectable, liposomal, injection), marketed as Daunoxome, Cerubidine, Daunorubicin Hydrochloride.

Registered studies
50+
Lab records
2
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Daunorubicin Citrate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acute myeloid leukemia
  • Lymphoid leukemia
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anthracyclines and related substances
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli30.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae28.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 2 of 2 lab records
Open Daunorubicin Citrate in ChEMBL Registered studies below
Show the 2 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Daunorubicin Citrate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma

    NCT04061772 · start 2019-08-12

    Registered record
    Registry ID
    NCT04061772
    Conditions
    Peripheral T Cell Lymphoma
    Interventions
    Bortezomib; Etoposide; Cyclophosphamide; Pharmorubicin; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2019-08-12
    Completion
    2021-12-05
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeripheral T Cell Lymphoma
    InterventionBortezomib; Etoposide; Cyclophosphamide; Pharmorubicin +1 more
    PhasePhase 2
    Registry statusUnknown

  • ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC

    NCT04172259 · start 2019-01-10

    Registered record
    Registry ID
    NCT04172259
    Conditions
    Breast Cancer; Neoadjuvant Chemotherapy
    Interventions
    Doxorubicin liposome; Cyclophosphamide; Trastuzumab; Docetaxel; Epirubicin; Pertuzumab; Paclitaxel; Paclitaxel-albumin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2019-01-10
    Completion
    2026-09-30
    Enrolment
    156

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Neoadjuvant Chemotherapy
    InterventionDoxorubicin liposome; Cyclophosphamide; Trastuzumab; Docetaxel +4 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor

    NCT03023124 · start 2018-03-04

    Registered record
    Registry ID
    NCT03023124
    Conditions
    Solitary Fibrous Tumors
    Interventions
    Trabectedin; Adriamycin; Dacarbazine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-03-04
    Completion
    2024-12-06
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolitary Fibrous Tumors
    InterventionTrabectedin; Adriamycin; Dacarbazine
    PhasePhase 2
    Registry statusCompleted

  • Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

    NCT02876302 · start 2018-01-24

    Registered record
    Registry ID
    NCT02876302
    Conditions
    Inflammatory Breast Cancer (IBC)
    Interventions
    Ruxolitinib; Paclitaxel; Doxorubicin; Cyclophosphamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-01-24
    Completion
    2024-10-01
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInflammatory Breast Cancer (IBC)
    InterventionRuxolitinib; Paclitaxel; Doxorubicin; Cyclophosphamide
    PhasePhase 2
    Registry statusCompleted

  • A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia

    NCT02954653 · start 2016-11-28

    Registered record
    Registry ID
    NCT02954653
    Conditions
    Acute Myeloid Leukemia
    Interventions
    PF-06747143; Cytarabine; Daunorubicin; Azacitidine; Decitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2016-11-28
    Completion
    2017-12-05
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia
    InterventionPF-06747143; Cytarabine; Daunorubicin; Azacitidine +1 more
    PhasePhase 1
    Registry statusTerminated

  • Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma

    NCT02871869 · start 2016-09

    Registered record
    Registry ID
    NCT02871869
    Conditions
    Diffuse, Large B-Cell, Lymphoma
    Interventions
    vindesine; cyclophosphamide; Epirubicin; prednisone tablets; Cinobufacini Tablets; Rituximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2016-09
    Completion
    2021-12
    Enrolment
    316

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiffuse, Large B-Cell, Lymphoma
    Interventionvindesine; cyclophosphamide; Epirubicin; prednisone tablets +2 more
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

    NCT02648477 · start 2016-03-28

    Registered record
    Registry ID
    NCT02648477
    Conditions
    Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Progesterone Receptor Negative; Progesterone Receptor Positive; Stage IV Breast Cancer; Triple-Negative Breast Carcinoma
    Interventions
    Anastrozole; Doxorubicin Hydrochloride; Exemestane; Laboratory Biomarker Analysis; Letrozole; Pembrolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-03-28
    Completion
    2023-12-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEstrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Progesterone Receptor Negative +3 more
    InterventionAnastrozole; Doxorubicin Hydrochloride; Exemestane; Laboratory Biomarker Analysis +2 more
    PhasePhase 2
    Registry statusCompleted

  • Treatment for Classical Hodgkin Lymphoma in Children and Adolescents

    NCT02797717 · start 2015-11

    Registered record
    Registry ID
    NCT02797717
    Conditions
    Classical Hodgkins Lymphoma in Children and Adolescents.
    Interventions
    Radiotherapy:; Vincristine; Etoposide; Prednisone; Doxorubicin; Dacarbazine; Cyclophosphamide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2015-11
    Completion
    2027-12
    Enrolment
    2,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClassical Hodgkins Lymphoma in Children and Adolescents.
    InterventionRadiotherapy:; Vincristine; Etoposide; Prednisone +3 more
    PhaseNot applicable
    Registry statusRecruiting

  • PDD vs PAD to Treat Initially Diagnosed MM

    NCT02577783 · start 2015-10

    Registered record
    Registry ID
    NCT02577783
    Conditions
    Multiple Myeloma
    Interventions
    PDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone; PAD regimen: bortizomib, dexamethasone and doxorubicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2015-10
    Completion
    2021-12
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionPDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone; PAD regimen: bortizomib, dexamethasone and doxorubicin
    PhasePhase 4
    Registry statusUnknown

  • Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

    NCT02356159 · start 2015-09-24

    Registered record
    Registry ID
    NCT02356159
    Conditions
    Myelodysplastic Syndromes; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Acute Leukemia; Multiple Myeloma
    Interventions
    Rituximab; Conditioning chemotherapy; TMS; FLAG; EPOCH-F; Hematopoietic stem cell transplant; Palifermin; Acetaminophen; Diphenhydramine; Prednisone; Epinephrine; IV Saline; ECG; ECHO; MUGA; DEXA; CT chest; PET; MRI; BM aspirate; BM biopsy; Lumbar puncture
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2015-09-24
    Completion
    2025-03-25
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyelodysplastic Syndromes; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Acute Leukemia +1 more
    InterventionRituximab; Conditioning chemotherapy; TMS; FLAG +18 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Neoadjuvant FDC With Melatonin or Metformin for Locally Advanced Breast Cancer.

    NCT02506777 · start 2015-07

    Registered record
    Registry ID
    NCT02506777
    Conditions
    Breast Cancer
    Interventions
    metformin; Fluoruracil; Doxorubicin; Cyclophosphamide; melatonin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2015-07
    Completion
    2020-08
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventionmetformin; Fluoruracil; Doxorubicin; Cyclophosphamide +1 more
    PhasePhase 2
    Registry statusUnknown

  • Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

    NCT02003222 · start 2014-05-19

    Registered record
    Registry ID
    NCT02003222
    Conditions
    Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
    Interventions
    Allogeneic Hematopoietic Stem Cell Transplantation; Biospecimen Collection; Blinatumomab; Bone Marrow Aspiration; Bone Marrow Biopsy; Cyclophosphamide; Cytarabine; Daunorubicin; Daunorubicin Hydrochloride; Dexamethasone; Etoposide; Leucovorin Calcium; Lumbar Puncture; Mercaptopurine; Methotrexate; Pegaspargase; Prednisone; Rituximab; Vincristine; Vincristine Sulfate; X-Ray Imaging
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2014-05-19
    Completion
    2027-02-25
    Enrolment
    488

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
    InterventionAllogeneic Hematopoietic Stem Cell Transplantation; Biospecimen Collection; Blinatumomab; Bone Marrow Aspiration +17 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma

    NCT01313884 · start 2011-05

    Registered record
    Registry ID
    NCT01313884
    Conditions
    Bone Cancer; Ewing's Sarcoma
    Interventions
    Irinotecan; Vincristine; Temozolomide; Doxorubicin; Cytoxan; Pegfilgrastim
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2011-05
    Completion
    2014-07
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBone Cancer; Ewing's Sarcoma
    InterventionIrinotecan; Vincristine; Temozolomide; Doxorubicin +2 more
    PhasePhase 2
    Registry statusTerminated

  • A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms

    NCT01309789 · start 2011-02

    Registered record
    Registry ID
    NCT01309789
    Conditions
    Lymphoma, Large-Cell, Anaplastic; Lymphoma, NK-cell; Lymphoma, T-cell
    Interventions
    brentuximab vedotin; cyclophosphamide; brentuximab vedotin; prednisone; cyclophosphamide; doxorubicin; doxorubicin; prednisone; vincristine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-02
    Completion
    2017-02-28
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma, Large-Cell, Anaplastic; Lymphoma, NK-cell; Lymphoma, T-cell
    Interventionbrentuximab vedotin; cyclophosphamide; brentuximab vedotin; prednisone +5 more
    PhasePhase 1
    Registry statusCompleted

  • International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia

    NCT01117441 · start 2010-06

    Registered record
    Registry ID
    NCT01117441
    Conditions
    Leukemia
    Interventions
    PEG-L-asparaginase; cyclophosphamide; cytarabine; daunorubicin hydrochloride; dexamethasone; doxorubicin hydrochloride; etoposide; ifosfamide; mercaptopurine; methotrexate; prednisone; thioguanine; vincristine sulfate; vindesine; daunoxome; fludarabine; Radiation Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-06
    Completion
    2021-12-31
    Enrolment
    6,136

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia
    InterventionPEG-L-asparaginase; cyclophosphamide; cytarabine; daunorubicin hydrochloride +13 more
    PhasePhase 3
    Registry statusCompleted